Company: BIAF
Filing Date: 2025-04-11
Form Type: S-1
Source: 0001641172-25-003892
Chunk: 74

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-11
Form: S-1
Chunk 74
---
 Common Stock is covered by analysts;                                                                             |
| ● | development of technological innovations or new competitive diagnostic tests or therapeutic products by others;                                                                                  |
| ● | announcements of technological innovations or new diagnostic tests or therapeutic products by us;                                                                                                |
| ● | our failure to achieve a publicly announced milestone;                                                                                                                                           |
| ● | delays between our expenditures to develop and market new or enhanced diagnostic tests or therapeutic products and the generation of sales from those diagnostic tests and therapeutic products; |
| ● | developments concerning intellectual property rights, including our involvement in litigation;                                                                                                   |
| ● | regulatory developments and the decisions of regulatory authorities as to the approval or rejection of new or modified diagnostic tests or therapeutic products;                                 |
| ● | changes in the amounts that we spend to develop, acquire, or license new diagnostic tests or therapeutic products, technologies, or businesses;                                                  |
| ● | changes in our expenditures to promote our diagnostic tests or therapeutic products;                                                                                                             |
| ● | our sale or proposed sale, or the sale by our significant shareholders, of our Common Stock or other securities in the future;                                                                   |
| ● | changes in key personnel;                                                                                                                                                                        |
| ● | success or failure of our research and development projects or those of our competitors;                                                                                                         |
| ● | the trading volume of our Common Stock; and                                                                                                                                                      |
| ● | general economic and market conditions and other factors, including factors unrelated to our operating performance.                                                                              |

These factors and any corresponding price fluctuations
may materially and adversely affect the market price of our Common Stock or Tradeable Warrants and result in substantial losses being
incurred by our investors. In the past, following periods of market volatility, public company shareholders have often instituted securities
class action litigation. If we were involved in securities litigation, it could impose a substantial cost upon us and divert the resources
and attention of our management from our business.

| 32 |

Our Common Stock has often been thinly traded, so investors may be unable to sell at or near ask prices or at all if investors need to sell shares to raise money or otherwise desire to liquidate their shares.

To date, there have been many days on which limited
trading of our Common Stock took place. We cannot predict the extent to which investors’ interests will lead to an active trading
market for our Common Stock or whether the market price of our Common Stock will be volatile. If an active trading market does not develop,
investors may have difficulty selling our Common Stock. We are likely to be too small to attract